Vertex Pharmaceuticals (VRTX) presented data over the weekend that could reshape treatment options for children suffering from two devastating blood disorders. The company shared results from multiple studies at the 2025 American Society of Hematology (ASH) Annual Meeting, demonstrating that its gene therapy Casgevy works in patients as young as 5 years old.

The therapy targets two conditions that make life extraordinarily difficult for young patients. Sickle cell disease (SCD) is a severe inherited blood disorder that damages red blood cells, restricts oxygen delivery throughout the body, triggers intense pain episodes, and can significantly shorten lifespan. Transfusion-dependent beta thalassemia (TDT) is equally challenging—a life-threatening genetic condition forcing patients to depend on regular blood transfusions and lifelong treatment to manage the dangerous iron buildup those transfusions create.

Breaking New Ground in Younger Patients

The most significant news involves children aged 5-11, marking the first time clinical data has ever been presented on any genetic therapy for this age group with sickle cell disease.

In the Phase 3 CLIMB-151 study for SCD, 11 children have been treated with Casgevy. All four patients with sufficient follow-up achieved the primary endpoint—remaining completely free from vaso-occlusive crises (VOCs) for at least 12 consecutive months. VOCs are excruciatingly painful episodes that occur when rigid, sickled red blood cells block small blood vessels. Even better, no patient experienced a VOC after receiving Casgevy, with one child remaining VOC-free for approximately two years.

The results for children with TDT are similarly encouraging. In the Phase 3 CLIMB-141 study, 13 patients have been dosed with Casgevy. All six patients with adequate follow-up achieved transfusion independence for at least 12 consecutive months while maintaining hemoglobin levels of at least 9 g/dL. Following treatment, 12 of the 13 patients are now transfusion-free, with the longest duration approaching two years.

There was one serious adverse event: a patient died from pneumonia in the context of multi-organ failure caused by severe veno-occlusive disease related to the busulfan conditioning regimen used to prepare patients for the therapy. This underscores that the treatment isn't without risks—the safety profile reflects the challenges of myeloablative conditioning and autologous transplant procedures.

Still, the data shows that children treated with Casgevy have durable increases in fetal hemoglobin and stable allelic editing, consistent with what researchers observed in older patients.

"These results, the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD, again demonstrate the transformative potential of CASGEVY," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex.

Long-Term Data Remains Strong

Beyond the pediatric data, Vertex also shared updated longer-term results from patients aged 12 and older in the pivotal clinical studies. The data, current as of April 2025, continues to demonstrate durable clinical benefits.

For SCD patients, 100% (45 out of 45) achieved freedom from VOCs for at least 12 consecutive months in either the CLIMB-121 or long-term follow-up study CLIMB-131, with patients remaining VOC-free for an average of 35.3 months.

In TDT patients, 98.2% (55 out of 56) achieved transfusion independence for at least 12 months in either CLIMB-111 or CLIMB-131, maintaining that independence for an average of 41.4 months.

VRTX Price Action: Vertex Pharmaceuticals shares were up 0.22% at $456.50 during premarket trading on Monday.